Cheng, H
Ballman, K
Vassilakopoulou, M
Dueck, A C
Reinholz, M M
Tenner, K
Gralow, J
Hudis, C
Davidson, N E
Fountzilas, G
McCullough, A E
Chen, B
Psyrri, A
Rimm, D L
Perez, E A
Article History
Received: 18 December 2013
Revised: 23 June 2014
Accepted: 13 July 2014
First Online: 12 August 2014
Competing interests
: Dr Gralow receives research funding from Amgen, Novartis, Roche, and Genentech. Dr Hudis receives research funding from Merck. Dr Rimm is a consultant for Genoptix/Novartis, the licensee of the Yale-owned AQUA technology used in this study. The remaining authors declare no conflict of interest.